Literature DB >> 29282683

Targeting Stemness: Implications for Precision Medicine in Breast Cancer.

Zhi-Mei Liang1, Yang Chen2, Man-Li Luo1.   

Abstract

The genomic landscape of breast cancer has been delineated in recent years. Advances in molecular characterization and targeting strategies are making it feasible to integrate clinical, genome-based and phenotype-based diagnostic and therapeutic methods and apply them to individual patient in the era of precision medicine. Cancer stem cells (CSCs) are a subpopulation in the tumor which have the capability of self-renewal and differentiation. Breast CSCs have important clinical implications as they account for tumor initiation, maintenance, metastasis, therapy resistance, and relapse. In this chapter, we will introduce approaches used to characterize breast CSCs, crucial pathways involved in regulating cancer stemness, and implications of breast CSCs in the precision diagnosis and treatment of breast cancer. We will also discuss novel compounds and therapeutic strategies that selectively target breast CSCs. Integration of breast CSC-related molecular diagnosis and targeted therapy into the clinical workflow of precision medicine has the potential to deliver more effective treatment to breast cancer patients.

Entities:  

Keywords:  Breast cancer; Cancer stem cell; Precision medicine

Mesh:

Year:  2017        PMID: 29282683     DOI: 10.1007/978-981-10-6020-5_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

1.  Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway.

Authors:  Kuen-Jang Tsai; Hsin-Yi Tsai; Chin-Chuan Tsai; Tai-Yu Chen; Tsung-Hua Hsieh; Chun-Lin Chen; Lulekiwe Mbuyisa; Yaw-Bin Huang; Ming-Wei Lin
Journal:  Molecules       Date:  2021-10-26       Impact factor: 4.411

2.  A Marine Collagen-Based Biomimetic Hydrogel Recapitulates Cancer Stem Cell Niche and Enhances Progression and Chemoresistance in Human Ovarian Cancer.

Authors:  SooHyeon Moon; YeJin Ok; SeonYeong Hwang; Ye Seon Lim; Hye-Yoon Kim; Yong-Jin Na; Sik Yoon
Journal:  Mar Drugs       Date:  2020-09-29       Impact factor: 5.118

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.